Pharmacokinetics of LFF571 and Vancomycin in Patients with Moderate Clostridium difficile Infections
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics of LFF571 and Vancomycin in Patients with Moderate Clostridium difficile Infections
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 3, Pages 1441-1445
Publisher
American Society for Microbiology
Online
2014-12-23
DOI
10.1128/aac.04252-14
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections
- (2014) Kathleen Mullane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications
- (2013) S. B. Debast et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ComparativeIn VitroActivities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria
- (2012) Diane M. Citron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection
- (2012) Anna Trzasko et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers
- (2012) Lillian S. L. Ting et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
- (2012) P. Sears et al. CLINICAL INFECTIOUS DISEASES
- Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
- (2012) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- (2011) F. Babakhani et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic absorption of oral vancomycin in patients with Clostridium difficile infection
- (2011) Sriharsha Rao et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis
- (2010) Shingo Chihara et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses
- (2008) Y. K. Shue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search